Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Digoxin in patients with advanced heart failure and sinus rhythm submitted to cardiac resynchronization therapy- is there any benefit?
Journal of Cardiovascular Pharmacology  (IF3.105),  Pub Date : 2021-11-03, DOI: 10.1097/fjc.0000000000001175
Cláudia Fernandes, Natália António, Vera Marinho, James Milner, Marta Madeira, Pedro A Sousa, Miguel Ventura, João Cristóvão, Luís Elvas, Lino Gonçalves

Digoxin use in patients with heart failure with reduced ejection fraction (HFrEF) and sinus rhythm remains controversial. We aimed to assess the prognostic impact of digoxin in patients in sinus rhythm submitted to cardiac resynchronization therapy (CRT).Retrospective study including 297 consecutive patients in sinus rhythm, with advanced HFrEF submitted to CRT. Patients were divided into two groups - with digoxin (DG) and without digoxin (NDG). During a mean follow-up of 4.9 ± 3.4 years we evaluated the impact of digoxin on the composite endpoint defined as cardiovascular hospitalization, progression to heart transplantation and all-cause mortality.Previous to CRT, 104 patients (35%) were chronically under digoxin and 193 patients (65%) without digoxin treatment. The 2 groups did not differ significantly regarding HF functional class, HF aetiology, QRS and baseline left ventricular ejection fraction (LVEF). The proportion of responders to CRT was similar in both groups (54% in DG vs 56% in NDG, p=0.78). During the long term follow up period, the primary endpoint occurred in a higher proportion in DG patients (67 vs 48%, p=0.002). After adjustment for potential confounders, digoxin use remained as an independent predictor of the composite endpoint of CV hospitalization, heart transplantation and all-cause mortality (HR = 1.58, CI 95 [1.01 - 2.46], p = 0.045).In conclusion, in patients in sinus rhythm with HFrEF submitted to CRT, digoxin use was associated to CV hospitalization, progression to heart transplant and all-cause mortality.